Penn Capital Management Company LLC Makes New $12.66 Million Investment in Amneal Pharmaceuticals, Inc. $AMRX

Penn Capital Management Company LLC purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,001,951 shares of the company’s stock, valued at approximately $12,655,000. Penn Capital Management Company LLC owned approximately 0.32% of Amneal Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Jefferies Financial Group Inc. purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $907,000. Global Retirement Partners LLC bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $115,000. Covestor Ltd grew its holdings in shares of Amneal Pharmaceuticals by 4,883.4% in the fourth quarter. Covestor Ltd now owns 9,618 shares of the company’s stock worth $121,000 after purchasing an additional 9,425 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Amneal Pharmaceuticals by 38.2% in the fourth quarter. Handelsbanken Fonder AB now owns 53,900 shares of the company’s stock worth $679,000 after purchasing an additional 14,900 shares during the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of Amneal Pharmaceuticals by 12.1% in the fourth quarter. ProShare Advisors LLC now owns 41,381 shares of the company’s stock worth $521,000 after purchasing an additional 4,461 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, May 11th. Barclays raised their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Truist Financial raised their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. UBS Group assumed coverage on shares of Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price on the stock. Finally, Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $15.17.

Insiders Place Their Bets

In related news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 17.30% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Stock Up 3.0%

NASDAQ:AMRX opened at $12.79 on Wednesday. The stock has a market cap of $4.08 billion, a P/E ratio of 33.66 and a beta of 1.32. The firm’s fifty day simple moving average is $12.58 and its 200 day simple moving average is $12.90. Amneal Pharmaceuticals, Inc. has a twelve month low of $7.07 and a twelve month high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.